We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

9 hedge funds and large institutions have $2.13M invested in Scinai Immunotherapeutics in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

10% less funds holding

Funds holding: 10 → 9 (-1)

15% less capital invested

Capital invested by funds: $2.51M → $2.13M (-$384K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Mariner
Mariner
Kansas
+$146K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$15K
2
UBS Group
UBS Group
Switzerland
-$10.8K

SCNI Hedge Fund Activity: Q4 2018 in Review

9 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2018, worth a combined $2.13M — down 15% from $2.51M a quarter earlier.

Fund positioning in SCNI was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Mariner, opening a new position worth an estimated $146K. The largest seller was Deutsche Bank, exiting entirely with an estimated $15K sold.

  • 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2018, down from 10 in Q3 2018.
  • Funds reported $2.13M of Scinai Immunotherapeutics stock for Q4 2018, down 15% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q4 2018 and 1 closed out, a net change of 0 holders.
  • The largest Scinai Immunotherapeutics buyer in Q4 2018 was Mariner, an estimated $146K added.
  • The largest Scinai Immunotherapeutics seller in Q4 2018 was Deutsche Bank, an estimated $15K sold.

Based on aggregated 13F filings for Q4 2018.